

As part of this study, I am receiving treatment with:

- ☐ JNJ-79635322 (BCMA x GPRC5D x CD3 Tri-Specific Antibody for Multiple Myeloma)
- ☐ Teclistamab (TECVAYLI)

If presenting for emergency treatment, please consider assessing for possible Cytokine Release Syndrome (CRS) and/or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) as part of the initial patient assessment.

Due to the potential seriousness of CRS/ICANS, all efforts should be made to medically assess the patient as soon as possible upon arrival at your Medical Center. For more information, please contact the treating physician or study sponsor at the numbers listed on this card.

Back Translated from Bengali to English on 03 Mar 2026

Johnson & Johnson

CARD FOR CLINICAL STUDY PARTICIPANT

*Global Version 1.0 09/Jan/2026
Country Version 1.0 18/Feb/2026*

PARTICIPANT CARD

Always show this card whenever you go to your physician or hospital, or in case of an **EMERGENCY**.

Participant's Name.....

Doctor in charge.....

Study Number **79635322MMY3002**

Hospital.....

Department.....

Site Number

Participant Number

24 hours emergency contact

This is a clinical study participant. If you are a healthcare professional and need information about the study or the study drug, please contact the investigator.

Local sponsor ☎: 000 80005 01161

Call the local sponsor only if you cannot contact the investigator and only in emergency situations.
Please do not provide your personal data; only provide the subject number.

Back Translated from Bengali to English on 03 Mar 2026